Patent · US Active

Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors

US7678811B2 · kind B2 · utility

42Cited by

131References

17Claims

0Family size

Assignee

BAYER HEALTHCARE LLC · DE

Inventors

Jacques Dumas · Neuilly-Plaisance, FR
William Scott · Guilford, US
Bernd Riedl · Wuppertal, DE

Key dates

Filing date	Jul 10, 2007
Grant date	Mar 16, 2010
Priority date	—
Expiry date	Oct 14, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D217/08
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angogenesis disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.